A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...

Viridian Therapeutics issued a press release that announced the positive elegrobart topline results from the phase 3 REVEAL-1 ...

The University of Rochester’s Flaum Eye Institute is embedding behavioral health into ophthalmology to improve patient care ...

A phase 1b randomized, head-to-head study suggests that the investigational VEGF/Ang2 bispecific antibody OLN324 may offer ...

Positive topline results from the phase 3 GLOW2 trial suggest that tarcocimab tedromer (Zenkuda), an investigational anti–vascular endothelial growth factor (VEGF) biologic, may offer durable disease ...

Chemical injuries to the ocular surface can be challenging to manage because they lie at the intersection of urgency and long-term consequences. The severity of these injuries dep ...

ELIOS achieved statistically significant, clinically meaningful IOP lowering, meeting both co-primary endpoints for responder ...

Major ophthalmic events in the first quarter of 2026 included treatments for presbyopia, age-related macular degeneration ...

Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...

NMPA authorization establishes a first-in-region, mechanism-based option for Demodex blepharitis in Greater China, where ...

In this episode of “iOpeners” from Ophthalmology Times, host Nicole Bajic, MD, comprehensive ophthalmologist at the Cole Eye ...

BCVA can remain deceptively stable until late RP and becomes insensitive at profound vision loss, motivating ...